Home › Trial NCT06166589
Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer
- Trial IDNCT06166589
- StatusNot Yet Recruiting
- PhasePhase 2
- Study typeInterventional
- SponsorShanghai Zhongshan Hospital
- Enrollment19
- Start date2024-01-01
- ConditionsPreviously AG Chemotherapy Treated Pancreatic Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.